Your fact-checks will appear here
The ongoing research into the use of ivermectin to treat cancer, including case reports and early trials.
Preclinical literature shows produces the most robust anticancer signals in (including triple‑negative), , , , (non‑small cell) and certain models, largely because it targets multiple survival and res...
Preclinical work identifies strongest anticancer signals for ivermectin in breast cancer, hematologic malignancies (notably leukemia), hepatocellular carcinoma, and several drug-resistant solid tumor ...
Standard single-dose antiparasitic regimens of oral ivermectin produce plasma levels in the low nanomolar range, whereas multi‑day oncology schedules being tested raise both total exposure and peak le...
Preclinical evidence places and its downstream Akt/mTOR axis as the single most consistently implicated route for —especially in where ivermectin promotes ubiquitin-mediated degradation of PAK1, reduc...
Preclinical anticancer activity of ivermectin has been demonstrated across cell lines and animal models, most commonly at micromolar concentrations in vitro (commonly ~3–5 µM) and at varying doses in ...
Preclinical research ties ’s anticancer activity to at least three interlocking mechanisms: suppression of Wnt/β‑catenin signaling, inhibition of the PAK1/Akt/mTOR axis with induction of autophagy/apo...
dosing for and is well established: onchocerciasis is typically treated with a single 150 micrograms per kilogram (mcg/kg) oral dose given at intervals (commonly annually) to suppress skin microfilari...
Preclinical mouse studies of ivermectin report effective antitumor activity across a wide dose range—commonly 0.5–10 mg/kg and in some reviews up to 40 mg/kg—with many experiments using ~3–10 mg/kg to...
Clinicians must identify or exclude high Loa loa microfilaremia before giving ivermectin in endemic areas because serious adverse events—including encephalopathy and death—are tightly linked to high c...